TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04159493
Drug: Estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal Application
Study: NCT04159493
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal Application
Study: NCT00049790
Drug: recombinant human Angiostatin protein
Normalized name: surfactant protein-D homotrimer, recombinant fragment human
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06518668
Drug: Cyclophosphamide LD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cy dose of 1 g/m2 administered IV over 30 to 60 minutes for the purpose of Lymphodepletion Therapy. Cyclophosphamide will help prepare your body to receive the treatment by decreasing the cells from your immune system to make space for the NKX019 cells.~(non-experimental)
Study: NCT04835389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline
Study: NCT05239650
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXA：85 mg/m2;LV:400 mg/m2；5-FU：400 mg/m2
Study: NCT05715840
Drug: SG001 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg，Q3W，IV infusion
Study: NCT05715840
Drug: SG001 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q3W，IV infusion
Study: NCT05928637
Drug: D745, D759, D150
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO for 5 days
Study: NCT04929067
Drug: immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma
Normalized name: pertussis, inactivated, whole cell, combinations with toxoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: immunotherapy combined with neoadjuvant chemotherapy in patients with locally advanced HPV (-) head and neck squamous cell carcinoma
Study: NCT05580107
Drug: MDPK67b
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg or 48 mg
Study: NCT05859776
Drug: AXT107 Mid Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single suprachoroidal injection of AXT107 (0.250 mg/eye)
Study: NCT06020885
Drug: Induction chemo-immunotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients receive 2-3 cycles of Abraxane 260mg/m2 d1+cisplatin 60mg/m2 d1+Toripalimab 240mg d1.
Study: NCT04723394
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (× 2 separate IM injections) of 600 mg of AZD7442 or saline placebo on Day 1.
Study: NCT05930119
Drug: HMPL-453
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg HMPL-453
Study: NCT05246644
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: we will use IV acetaminophen and an oral placebo or IV placebo and active oral acetaminophen
Study: NCT05199142
Drug: SDI-118
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDI-118 Powder in Capsules (PiC) are presented as Drug Substance in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules. No excipients are added.
Study: NCT05199142
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Matching Placebo for SDI-118 PiC is equivalent dose of mannitol (an inert excipient) in white, size 3, hydroxypropylmethylcellulose (HPMC) capsules.
Study: NCT01003405
Drug: KUC-7483
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06247046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Powder
Study: NCT05116111
Drug: SYHA1402 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYHA1402 tablets, oral, twice daily
Study: NCT05116111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral, twice daily
Study: NCT06162988
Drug: 68Ga-NOTA-H006 is injected intravenously with a dose of 1.8 MBq[0.05MCi]/kg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga-NOTA-H006：PET imaging； 18F-FDG：PET imaging
Study: NCT06350812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously once a week
Study: NCT01255501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04702256
Drug: Administration of methylprednisolone, paracetamol and dexchlorpheniramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to infusion of obinutuzumab, patients receiving obinutuzumab will receive premedication including 100 mg of methylprednisolone, paracetamol and dexchlorpheniramine.
Study: NCT04989387
Drug: INCA00186
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCA00186 will be administered every 2 weeks or 4 weeks as per protocol
Study: NCT04989387
Drug: INCB106385
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB106385 will be administered orally once or twice a day.
Study: NCT05766969
Drug: CBD/PEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: A water-soluble sublingual tablet containing 10/50 mg of CBD/PEA.
Study: NCT05766969
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An inactive compound.
Study: NCT05872685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative placebo, 300 mg IV infusion
Study: NCT05761405
Drug: Amikacin
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.
Study: NCT00002328
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04761601
Drug: UCT-01-097
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally available kinase inhibitor
Study: NCT00663624
Drug: Usual care as prescribed by the ED physicians.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care can be oral anti-diabetic agents, subcutaneous insulin therapy or a combination of both. Subcutaneous insulin used for usual care could include NPH, 70/30 insulin, aspart insulin, regular insulin or insulin glargine
Study: NCT05933213
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: glucocorticoids
Study: NCT06133049
Drug: No DMTs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women with MS not exposed to any DMTs during pregnancy
Study: NCT05124067
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive normal saline.
Study: NCT05498792
Drug: CBL0137
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will be enrolled at 3 dose levels of CBL 0137, dose level -1 (320 mg/m²), dose level 1 (400 mg/m²), dose level 2 (540 mg/m²)
Study: NCT05098028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Twice Daily
Study: NCT04319367
Drug: Investigational Medicinal Product
Normalized name: Percy Medicine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human monoclonal antibody (mAb) or placebo
Study: NCT05089409
Drug: ATB1651, 2 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will apply daily doses of ATB1651, 2 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
Study: NCT05089409
Drug: ATB1651, 5 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will apply daily doses of ATB1651, 5 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
Study: NCT05089409
Drug: ATB1651, 10 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will apply daily doses of ATB1651, 10 mg/mL to all 10 toenails including at least 1 affected great toenail for 28 days
Study: NCT05925920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of placebo comparator
Study: NCT05833906
Drug: CKR-051 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered 5 g of CKR-051.
Study: NCT05833906
Drug: CKR-051 Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered 10 g of CKR-051.
Study: NCT05833906
Drug: CKR-051 Dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered 10 g of CKR-051.
Study: NCT05833906
Drug: CKR-051 Dose 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered 10 g of CKR-051.
Study: NCT05833906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator.
Study: NCT04854395
Drug: Marcain 5 mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total volumes of Marcain differs in each arm, depending on which nerve blocks the patients is randomized to receive. Sham block does not include injection of placebo saline, due to the risk of hydrodissection between the anatomical sections which may erase the isolation of the different nerve blocks. Instead the sham block include imitation of the real nerve block, including correct placement of the needle on the target for the block.
Study: NCT04663321
Drug: MK-1942
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1942 (5 mg or 10 mg capsules) titrated from 5 mg to 20 mg dose BID or 10 mg BIW over 4 weeks.
Study: NCT04663321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose matched placebo capsules BID orally over 4 weeks.
Study: NCT06538584
Drug: Caffeine citrate 10mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized prior to surgery into one of two arms. One arm will receive 10mg/kg Caffeine citrate 15 minutes post surgery.
Study: NCT06538584
Drug: 0.9% Sodium Citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized prior to surgery into one of two arms. One arm will receive 0.9% Sodium Citrate/kg 15 minutes post surgery.
Study: NCT03324867
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
Study: NCT03324867
Drug: Normal Saline Flush, 0.9% Injectable Solution
Normalized name: Normal Saline Flush, 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
Study: NCT00000756
Drug: Lymphocytes, Activated
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05806060
Drug: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.
Study: NCT05806060
Drug: nab-paclitaxel, with maintenance of capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.
Study: NCT04714554
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin 500-mg tablets; oral administration.
Study: NCT04775485
Drug: DAY101
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAY101 is an oral pan-RAF inhibitor provided as an immediate-release tablet (100 mg) or powder for reconstitution (25 mg/mL).
Study: NCT04750070
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children will receive dopamine, 8 microgram/kg.min (increasing the dose after 15 minutes to 12 microgram/kg/min to a maximum of 15 microgram/kg/min)
Study: NCT04750070
Drug: Blood Transfusion
Normalized name: Blood transfusion, auxiliary products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children will receive a transfusion of whole human blood in a dose of 10 mL/kg over 2-3 hours. While the blood transfusion is being arranged, IV fluid would be given @ of 3 ml per kg per hour
Study: NCT05857215
Drug: amilo-5MER
Normalized name: amilomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: amilo-5MER is a 5 amino acid synthetic peptide MTADV (Methionine, Threonine, Alanine, Aspartic acid, Valine).
Study: NCT04530747
Drug: Placebo oral capsule + PAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to this arm will receive 500 mg capsules containing placebo. Placebo dosing will be 500 mg (1 x 500 mg) qPM during Week 1, 1000 mg (2 x 500 mg) qPM during Week 2, 1500 mg (3 x 500 mg) qPM during Week 3, and 2000 mg (4 x 500 mg) qPM from Week 4 onwards.~Subjects will also be provided PAP (positive airway pressure) device for standard management of obstructive sleep apnea.
Study: NCT06339281
Drug: apatinib mesylate+Capecitabine Tablets
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Capecitabine Tablets: 1000 mg/m2, po, twice a day, d1-d14, discontinued for 1 week after 2 weeks of treatment;
Study: NCT05707520
Drug: enteric-coated mycophenolate (MPAs)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immunosuppression protocol with enteric-coated mycophenolate sodium
Study: NCT05204394
Drug: VM-1500A-LAI
Normalized name: laidlomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable nanoformulation of depulfavirine (parent drug of elsulfavirine)
Study: NCT05841277
Drug: LY3819469
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT04938908
Drug: Ophthalmic Probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacterial lysate of Lactobacillus sakei, hydroxypropylmethylcellulose (HPMC), boric acid, sodium chloride, purified water.
Study: NCT04938908
Drug: Opthalmic Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains complete formulation of the active drug except for bacterial lysate of Lactobacillus sakei (i.e. HPMC, boric acid, sodium chloride, purified water)
Study: NCT05119790
Drug: [14C] BIIB122 ([14C] DNL151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose
Study: NCT02153541
Drug: Antipyrine-benzocaine otic solution
Normalized name: antipyrine / benzocaine Otic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receiving antipyrine-benzocaine otic solution are expected to decrease usage of rescue inhalers.
Study: NCT04833049
Drug: [14C]TAK-994 Intravenous Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]TAK-994 intravenous infusion.
Study: NCT04833049
Drug: [14C]TAK-994 Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]TAK-994 oral suspension.
Study: NCT04600752
Drug: Augmentin (ES)-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentin ES will be administered as reconstituted oral suspension containing Amoxicillin and Potassium Clavulanate 600 mg/42.9 mg per 5 milliliters.
Study: NCT05413668
Drug: RVP-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of RVP-001
Study: NCT05413668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of saline placebo
Study: NCT02664740
Drug: Topical anti-Staphylococcus bacteriophage therapy
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the experimental arm will receive sterile compress dressings impregnated with a phage solution of 10\^7 PFU/ml on days 0, 7 and 14 (unless the wound is already healed, i.e. phage solutions are not applied to healed wounds).
Study: NCT02664740
Drug: Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the placebo arm will receive sterile compress dressings impregnated with a placebo solution on days 0, 7 and 14 (unless the wound is already healed, i.e. placebo solutions are not applied to healed wounds).
Study: NCT06277609
Drug: Acetylsalicylic Acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet
Study: NCT06277609
Drug: Mefenamic Acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet
Study: NCT05972122
Drug: Analgesia management; group S and C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient-controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol including 10 mcg bolus without infusion dose, 10 min lockout time, and 4-hour limit. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
Study: NCT04812236
Drug: Wulingsan co-decoction granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wulingsan co-decoction granules, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
Study: NCT04812236
Drug: Wulingsan granule simulant
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wulingsan granule simulant, the prescription is Alisma, Polyporus, Atractylodes, Poria, Guizhi. Oral, 2 times a day, 2 sachets each time, rinsed with warm water
Study: NCT04144933
Drug: Acetaminophen, Gabapentin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 975 mg, 300 mg
Study: NCT04826172
Drug: IMB-1018972
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified release (MR) oral tablet
Study: NCT04826172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral tablet
Study: NCT04144933
Drug: Sevoflurane, Sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose titrated to effect, As needed (dose at anesthesiologist's discretion)
Study: NCT05229562
Drug: BIIB122
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT05071794
Drug: saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05626959
Drug: NTI164
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil based. Full-spectrum medicinal cannabis plant extract with less than 0.08% THC.
Study: NCT05591755
Drug: Experimental: Vehicle ophthalmic solution (n = 56)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental: Vehicle ophthalmic solution (n = 56)
Study: NCT06223048
Drug: AMDX-2011P
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMDX-2011P single bolus injection intravenous for diagnostic review
Study: NCT06331494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butylphthalide Placebo injection for 10±3 days, oral Butylphthalide Placebo soft capsules for day 11±3 to day 180.
Study: NCT06394375
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given as analgesia in opioid balanced anesthesia (control) group
Study: NCT05186363
Drug: Chemopreventive Agent - SPAQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal malaria chemoprevention (SMC) is a highly effective community-based intervention to prevent malaria infections in areas where the malaria burden is high and transmission occurs mainly during the rainy season. It involves administering monthly courses of sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) during this peak transmission period to those most at risk: children 3-59 months.
Study: NCT05186363
Drug: Control Test - no drugs given
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is where children aged 3-59 months do not receive any chemoprevention drugs but do receive health promotion messages and visit from health workers similar to the chemoprevention SPAQ arm.
Study: NCT06096012
Drug: Anti-MRSA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: chart review to determine the clinical outcomes of patients with osteomyelitis who were placed on definitive anti-MRSA treatment, despite no identified MRSA cultures.
Study: NCT05234853
Drug: PUR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody
Study: NCT05232461
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib
Study: NCT06248229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing will begin the morning following Visit 2. Subjects in the placebo group will begin the study on 5 mg of placebo. Subjects will be advised to take one tablet each morning upon awakening, dosed consistently with respect to time. Subjects will be advised that tablets should be swallowed whole, not crushed, chewed, or cut. Subjects can take Dyanavel XR with or without food.~Subjects will return to the study site on a weekly (and later, bi-weekly) basis for evaluation of symptoms and possible side effects. Subjects will be titrated to their optimal dose based on the dose titration schedule displayed in Section 5.1. The PI will be available to consult with patients as needed between Week 0 and Week 4 to adjust dosage per the PI's clinical judgment.
Study: NCT06217939
Drug: Early hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For the Early Hydrocortisone group, 50 mg of hydrocortisone in 10 ml of normal saline will be given as an intravenous bolus, then 200 mg of hydrocortisone in 100 ml of normal saline will be given as continuous intravenous infusion in 24 hours for 2 consecutive days (total 250 mg in day 1 and 200 mg in day 2).~After completion of the study drugs for 2 days, the study drug will be discontinued without tapering.
Study: NCT06217939
Drug: Open-label hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: An open-label 50 mg of hydrocortisone given as an intravenous bolus followed by intravenous hydrocortisone 200 mg/day given as continuous infusion or divided bolus administration is suggested to be commenced in both study arms if the hemodynamic goal of the patient is not reached despite the dose of norepinephrine or epinephrine ≥ 0.25 mcg/kg/min at least 4 hours after the initiation of the vasopressors as recommended by the guideline. The study drug in each arm will be discontinued once an open-label hydrocortisone is initiated. Capillary or venous blood glucose will be tested at least every 6 hours for 2 days then at least once daily or more as appropriate for the first 7 days as a part of the study protocol.
Study: NCT06106685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will be given equal volume placebo (120ml carrier solution matching the volume of WMT-001), which contains 10% sterile glycerol and saline injection. The drug was administered once a day for 4 days.
Study: NCT05990452
Drug: 9MW2921
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive 9MW2921 by intravenous (IV) every 3 weeks.